EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

NCT00647192 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

38

Enrollment

OTHER

Sponsor class

Stopped Inclusion rate too low. Recruitment of further study centers too costly.

Conditions

Atrial Fibrillation

Interventions

DRUG: Eplerenone
DRUG: Placebo

Sponsor

University Hospital, Saarland

Collaborators

[object Object]
[object Object]